RACEMATE

A RAndomised Placebo Controlled Trial - to Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis with Polyangiitis

Eosinophilic granulomatosis with polyangiitis (EGPA) is a complex chronic disease, characterised by asthma, Sino-nasal disease, neuropathy and eosinophilic vasculitis of target organs. 

The RACEMATE study aims to investigate the role of thymic Stromal Lymphopoietin (TSLP) and alarmin biology in EGPA. The trial is important as pre-clinical evidence suggests that alarmins are critical in the induction of vasculitis in EGPA and may ultimately lead to new treatments for this rare and complex disease.  

We hypothesise that Targeting TSLP in eosinophilic granulomatosis with polyangiitis (EGPA) with Tezepelumab - will improve the likelihood of EGPA remission and that the mechanism of action of Tezepelumab is via reduced systemic and tissues alarmins, and tissue innate lymphoid type 2 (ILC-2) cells.

RACEMATE is a randomised (1:1 allocation), double blind, placebo-controlled trial. The trial will recruit 62 adult patients, with a clinician diagnosis of EGPA receiving a stable dose of oral prednisolone (≥5.0 to ≤30.0 mg per day, with or without additional Immunosuppressive therapy) for at least four weeks before the baseline visit (V2).
Patients will be recruited from 16 to 20 specialist sites in the United Kingdom.